Lacosamide Injection, Solution
Product Images NDC 68462-697

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 68462-697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Carton (Carton)

Carton (Carton)
This text is a description of a medication product - Lacosamide Injection, USP, distributed by Glenmark Pharmaceuticals Inc. The solution is for infusion and comes in single-dose vials of 20 mL containing 200 mg of Lacosamide, USP. The inactive ingredients include sodium chloride and hydrochloric acid for pH adjustment. The usual dosage is provided in the package insert. It is for intravenous use only, and pharmacists are instructed to dispense the medication guide to each patient and discard any unused portion. The storage conditions are specified as 20°C to 25°C with permitted excursions between 15°C to 30°C. It is essential to keep the product out of reach of children. The product is a controlled room temperature medication.*
FDA Label Image

"image Description" (Fig 1 Laco Spl)

"image Description" (Fig 1 Laco Spl)
This text provides information regarding seizure reduction through the median percentage change from baseline in two studies (Study 3 and Study 4) involving the use of Lacosamide and placebo. It indicates statistically significant differences in seizure reduction when comparing Lacosamide to placebo.*
FDA Label Image

"image Description" (Fig 2 Laco Spl)

"image Description" (Fig 2 Laco Spl)
This information shows the responder rate for different dosages of lacosamide compared with a placebo. The responder rate represents the percentage of patients who experienced an improvement, remained stable, or worsened in their condition. The data is presented for different dosages of lacosamide (200mg/day, 400mg/day, and 600mg/day) compared to a placebo, with the number of patients in each group indicated in parentheses.*
FDA Label Image

"image Description" (Fig 3 Laco Spl)

"image Description" (Fig 3 Laco Spl)
This text provides statistical information on patient proportions, including a p-value of 0.001, hazard ratio of 0.548 indicating a risk reduction of 45.2%, and a confidence interval of 95% (0381, 0788). It also references the number of risk factors and mentions time in terms of days.*
FDA Label Image

Label (Label)

Label (Label)
This text contains information about a medication labeled as Lacosamide, provided in an injection form with a concentration of 200 mg/20 mL. It is intended for intravenous use only and comes in a single-dose vial. The usual dosage instructions can be found in the package insert, and any unused portion should be discarded. The medication should be stored at 20-25°C, with permissible excursions between 15-30°C. It is important to keep this medication out of reach of children. This specific product is distributed by Glenmark Pharmaceuticals Inc. in the USA and is a product of India. The manufacturing license number is TS/S6Y/2023-112201.*
FDA Label Image
Logo (Logo)
FDA Label Image

Logo1 (Logo1)

Logo1 (Logo1)
FDA Label Image

"image Description" (Structure Laco Spl)

"image Description" (Structure Laco Spl)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.